25 September 2026
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ross McAloon Lead | Latham & Watkins LLP | Partner | Capital Markets | Orange County |
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | Capital Markets | Orange County |
| Matt Bush | Latham & Watkins LLP | Partner | Capital Markets | San Diego |
| Greg Rodgers | Latham & Watkins LLP | Partner | Capital Markets | New York/Los Angeles |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 500m (US$500 Million)
- What the figure measures
- Total transaction value
- Client
- Latham & Watkins LLPUnderwriters
- Counterparties
- Viking Therapeutics, Inc. (Issuer)